Barclays raised the firm’s price target on MacroGenics (MGNX) to $6 from $4 and keeps an Overweight rating on the shares. The firm adjusted ratings and targets in the small and mid cap biotechnology group as part of a Q1 earnings preview.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MGNX:
- MacroGenics Nears Key Prostate Cancer Catalyst as Phase 2 Lorigerlimab Trial Completes
- MacroGenics upgraded to Buy at B. Riley after deal for Tubulus
- MacroGenics upgraded to Buy from Neutral at B. Riley
- MacroGenics Resumes LINNET Trial After FDA Hold Lifted
- MacroGenics says FDA removes partial clinical hold on Phase 2 LINNET study